



Dr. Ricardo ROCHA, Intellia Therapeutics

Ricardo Rocha, MD studied medicine at the National University of Colombia, and completed his research training in Cardiovascular and Renal Pharmacology at New York Medical College and Endocrine-Hypertension at the Brigham and Women's Hospital, Harvard Medical School.

Ricardo was elected Fellow of the American Heart Association in 2001 and received scientific awards from the American Society of Hypertension and the American Heart Association. He has a solid track record in industry with nearly 25 years of experience, first at Pharmacia/Pfizer and later joining Novartis in 2003 where he had significant contributions to the development of Novartis' cardiovascular pipeline in the USA as well as in Global Medical Affairs. Ricardo played a major role on the successful launch of multiple products such as Diovan, Exforge and Entresto.

Since May 2022, Ricardo has been serving as the Head of Medical Affairs at Intellia Therapeutics, Inc. where he is contributing to the development of CRISPR-based therapies for the treatment of multiple diseases such as ATTR-Amyloidosis and Hereditary Angioedema.